GlaxoSmithKline PLC ADR (GSK) — Quality & forensics

As of 2026-09-03 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.

The Closelook module scores

52 /100 composite · 7 modules · general weight set

Valuation 53
Quality 76
Growth 35
Balance sheet 46
Cash quality 45
Capital allocation 61
Momentum 40

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

2.49 Altman Z-Score

Sits in the grey zone (1.81–2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

9/9 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

-2.28 Beneish M-Score

Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.

Continue: the GSK chart & overview

FAQ · from the current data · as of 2026-09-03

Quick answers

What is GlaxoSmithKline PLC ADR's Closelook quality reading?

The composite reads 52/100 across 7 modules, as of 2026-09-03: valuation 53, quality 76, growth 35, balance sheet 46, cash quality 45, capital allocation 61, momentum 40. Closelook scores are research diary readings, not ratings or investment advice.

What is GlaxoSmithKline PLC ADR's Altman Z-Score?

2.49, which sits in the grey zone (1.81–2.99) as of 2026-09-03. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is GlaxoSmithKline PLC ADR's Piotroski F-Score?

9 of 9, as of 2026-09-03. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

What does GlaxoSmithKline PLC ADR's Beneish M-Score indicate?

-2.28 — below the −1.78 manipulation-risk threshold, as of 2026-09-03. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.